18 December 2025
HARWORTH GROUP PLC (‘Harworth’ or the ‘Group’ or the ‘Company’) Harworth secures 267,000 sq ft of I&L Investment Portfolio lettings, delivering £2.5m of annualised…
17 December 2025
LONDON STOCK EXCHANGE ANNOUNCEMENT JPMORGAN INDIA GROWTH & INCOME PLC FINAL RESULTS FOR THE YEAR ENDED 30TH SEPTEMBER 2025 Legal Entity Identifier: 549300OHW8R1C2WBYK02 Information…
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma · Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients…
16 December 2025
Full Year Results for the year ended 30 September 2025 Resilient FY25 performance with £2bn of future pipeline opportunities The Group announces its annual…
GOODWIN PLC CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS for the half year ended 31st October 2025 CHAIRMAN’S STATEMENT The Board reports a solid trading performance…
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps · First and only ultra-long-acting biologic with…
16 December 2025 Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus Convenient subcutaneous option has potential to reach…
16 December 2025 Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive…